Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MYMD MyMD Pharmaceuticals	$0.09 +0.2%	$0.12	$1.75 ▼ $63.90	$225K	2.15	134,123 shs	72.39 million shs
NMTR 9 Meters Biopharma		$0.00	$0.07 ▼ $6.56	$1.04M	1.36	315,915 shs	6 shs
PTPI Petros Pharmaceuticals	$0.03 -2.4%	$0.03	$0.02 ▼ $16.25	$897K	1.56	5.01 million shs	73,527 shs
SLRX Salarius Pharmaceuticals	$5.32 -2.2%	$11.02	$4.76 ▼ $108.00	$770K	0.45	431,513 shs	39,381 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MYMD MyMD Pharmaceuticals	-6.97%	-13.91%	+8.23%	-38.43%	-94.88%
NMTR 9 Meters Biopharma	0.00%	0.00%	-99.72%	-99.72%	-81.82%
PTPI Petros Pharmaceuticals	0.00%	+1.37%	+5.36%	-37.63%	-99.68%
SLRX Salarius Pharmaceuticals	-3.89%	-25.04%	-50.05%	-53.36%	-82.05%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
MYMD MyMD Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NMTR 9 Meters Biopharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PTPI Petros Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SLRX Salarius Pharmaceuticals	0.1308 of 5 stars	0.0	2.0	0.0	0.0	2.0	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating	Consensus Price Target	% Upside from Current Price
MYMD MyMD Pharmaceuticals	N/A	N/A	N/A
NMTR 9 Meters Biopharma	N/A	N/A	N/A
PTPI Petros Pharmaceuticals	N/A	N/A	N/A
SLRX Salarius Pharmaceuticals	N/A	N/A	N/A

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
MYMD MyMD Pharmaceuticals	N/A	N/A	N/A	N/A	$7.21 per share	N/A
NMTR 9 Meters Biopharma	N/A	N/A	N/A	N/A	$0.19 per share	N/A
PTPI Petros Pharmaceuticals	$5.11M	0.18	N/A	N/A	$4.04 per share	0.01
SLRX Salarius Pharmaceuticals	N/A	N/A	N/A	N/A	($5.85) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
MYMD MyMD Pharmaceuticals	-$4M	N/A	0.00	∞	N/A	N/A	-179.05%	-108.14%	N/A
NMTR 9 Meters Biopharma	-$43.77M	-$3.46	N/A	N/A	N/A	N/A	-584.97%	-159.45%	N/A
PTPI Petros Pharmaceuticals	-$8.16M	-$52.91	N/A	∞	N/A	N/A	-78.22%	-23.50%	N/A
SLRX Salarius Pharmaceuticals	-$5.58M	-$2.90	N/A	∞	N/A	N/A	-556.47%	-192.35%	N/A

Latest MYMD, NMTR, SLRX, and PTPI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/12/2025	Q2 2025	SLRX Salarius Pharmaceuticals	-$33.00	-$0.45	+$32.55	-$0.45	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
MYMD MyMD Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
NMTR 9 Meters Biopharma	N/A	N/A	N/A	N/A	N/A
PTPI Petros Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SLRX Salarius Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
MYMD MyMD Pharmaceuticals	N/A	0.62	0.62
NMTR 9 Meters Biopharma	N/A	0.59	0.59
PTPI Petros Pharmaceuticals	1.58	0.85	0.74
SLRX Salarius Pharmaceuticals	N/A	0.61	0.61

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
MYMD MyMD Pharmaceuticals	9.64%
NMTR 9 Meters Biopharma	22.34%
PTPI Petros Pharmaceuticals	12.34%
SLRX Salarius Pharmaceuticals	11.88%

Insider Ownership

Company	Insider Ownership
MYMD MyMD Pharmaceuticals	2.12%
NMTR 9 Meters Biopharma	2.40%
PTPI Petros Pharmaceuticals	8.23%
SLRX Salarius Pharmaceuticals	1.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
MYMD MyMD Pharmaceuticals	6	2.37 million	2.32 million	Optionable
NMTR 9 Meters Biopharma	20	14.34 million	13.99 million	No Data
PTPI Petros Pharmaceuticals	20	31.16 million	9.93 million	Not Optionable
SLRX Salarius Pharmaceuticals	20	140,000	140,000	Not Optionable

MYMD, NMTR, SLRX, and PTPI Headlines

Recent News About These Companies

Salarius Pharmaceuticals Inc (SLRX) - Investing.com

August 20 at 5:54 PM | investing.com

Salarius Pharmaceuticals Appoints New Acting CEO

August 19 at 9:25 AM | msn.com

Salarius Pharmaceuticals files $50M mixed securities shelf

August 16, 2025 | msn.com

Salarius Pharmaceuticals trading halted, news pending

August 16, 2025 | msn.com

Salarius Pharmaceuticals Announces Reverse Stock Split

August 16, 2025 | msn.com

Salarius Pharmaceuticals, Inc.: Salarius Pharmaceuticals Announces 1-for-15 Reverse Stock Split

August 14, 2025 | finanznachrichten.de

Salarius Pharmaceuticals Announces 1-for-15 Reverse Stock Split

August 14, 2025 | globenewswire.com

Salarius Pharmaceuticals Raises $3.8M Through Stock Sale

July 31, 2025 | msn.com

Salarius Pharmaceuticals Modifies Security Holders’ Rights

July 30, 2025 | msn.com

Salarius Pharmaceuticals stock soars after Nasdaq extends compliance deadline

July 29, 2025 | investing.com

Salarius Pharmaceuticals Granted Additional Extension to Regain Compliance with Nasdaq’s Stockholders’ Equity Standard

July 14, 2025 | finance.yahoo.com

Salarius Pharmaceuticals Granted Additional Extension to Regain Compliance with Nasdaq's Stockholders' Equity Standard

July 14, 2025 | globenewswire.com

Salarius Pharmaceuticals’ Seclidemstat Demonstrates Supporting Role ...

July 11, 2025 | morningstar.comM

Salarius Pharmaceuticals shareholders approve reverse stock split and share issuance

July 10, 2025 | uk.investing.com

Salarius Pharmaceuticals’ Seclidemstat Demonstrates Supporting Role in Inhibiting Validated Oncology Target LSD1 in Two Recently Published Studies

July 10, 2025 | finance.yahoo.com

Salarius Pharmaceuticals' Seclidemstat Demonstrates Supporting Role in Inhibiting Validated Oncology Target LSD1 in Two Recently Published Studies

July 9, 2025 | globenewswire.com

Salarius Granted Nasdaq Extension To Regain Compliance With Listing Standards

June 18, 2025 | nasdaq.com

Salarius Pharmaceuticals faces Nasdaq delisting over rule breaches

April 27, 2025 | investing.com

Salarius Pharmaceuticals announces Langer to join SAB

April 17, 2025 | markets.businessinsider.com

Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Appoints Renowned MIT Professor Robert S. Langer to its Scientific Advisory Board

April 16, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MYMD, NMTR, SLRX, and PTPI Company Descriptions

MyMD Pharmaceuticals NASDAQ:MYMD

$0.09 +0.00 (+0.21%)

As of 08/20/2025

MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the aging and age-related and autoimmune diseases, and chronic pain, anxiety, and sleep disorders. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immune system and its pro-inflammatory cytokines to prevent and treat autoimmune diseases and age-related illnesses, and a Phase 2 clinical trial for sarcopenia, multiple sclerosis, diabetes, inflammatory bowel diseases, and rheumatoid arthritis; inflammation related depression and anxiety; and COVID-19-associated depression. It is also developing Supera-CBD, a synthetic analog of cannabidiol for treating epilepsy, pain, and anxiety/depression. The company was founded in 2014 and is headquartered in Baltimore, Maryland.

9 Meters Biopharma NASDAQ:NMTR

9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders in North America. Its lead product candidate is Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 3 clinical trial to treat short bowel syndrome. The company is developing NM-136, a humanized monoclonal antibody for the treatment of obesity and obesity-related disorders; NM-102, a small molecule peptide to prevent antigens from trafficking into systemic circulation; and NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease. Its partnered product is Larazotide, an 8-amino acid peptide, which is in Phase 2 clinical trial for treatment of multi-system inflammatory syndrome. The company has licensing agreements with Amunix, MHS Care Innovation LLC, Alba Therapeutics Corporation, and EBRIS. 9 Meters Biopharma, Inc. is headquartered in Raleigh, North Carolina. On July 17, 2023, 9 Meters Biopharma, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the Eastern District of North Carolina.

Petros Pharmaceuticals NASDAQ:PTPI

$0.03 0.00 (-2.37%)

As of 03:59 PM Eastern

Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health products, including vacuum erection devices, penile injections, PreBoost, VenoSeal, and urinary tract infection tests for the treatment of erectile dysfunction. Petros Pharmaceuticals, Inc. is based in New York, New York.

Salarius Pharmaceuticals NASDAQ:SLRX

$5.32 -0.12 (-2.21%)

Closing price 04:00 PM Eastern

Extended Trading

$5.26 -0.06 (-1.15%)

As of 07:50 PM Eastern

Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds and Cancer Prevention and Research Institute of Texas for product development activities. The company is headquartered in Houston, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time